Anchor Capital Advisors LLC Sells 50,883 Shares of Eton Pharmaceuticals, Inc. $ETON

Anchor Capital Advisors LLC cut its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 58.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,778 shares of the company’s stock after selling 50,883 shares during the period. Anchor Capital Advisors LLC owned about 0.14% of Eton Pharmaceuticals worth $799,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Man Group plc increased its holdings in Eton Pharmaceuticals by 6.0% in the 2nd quarter. Man Group plc now owns 23,754 shares of the company’s stock valued at $338,000 after buying an additional 1,350 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $30,000. AlphaQuest LLC raised its position in Eton Pharmaceuticals by 44.4% in the second quarter. AlphaQuest LLC now owns 5,948 shares of the company’s stock worth $85,000 after purchasing an additional 1,830 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in Eton Pharmaceuticals during the second quarter worth about $37,000. Finally, Legal & General Group Plc acquired a new stake in Eton Pharmaceuticals during the second quarter valued at approximately $41,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ETON. Wall Street Zen cut Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Eton Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $29.67.

Eton Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ:ETON opened at $15.17 on Thursday. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. The firm has a market cap of $406.86 million, a P/E ratio of -60.68 and a beta of 1.18. Eton Pharmaceuticals, Inc. has a 12 month low of $11.09 and a 12 month high of $23.00. The company’s 50-day moving average price is $16.28 and its two-hundred day moving average price is $17.02.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, November 6th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.20). Eton Pharmaceuticals had a negative return on equity of 11.32% and a negative net margin of 9.50%.The company had revenue of $22.46 million during the quarter, compared to the consensus estimate of $20.47 million. As a group, research analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.